A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunteers
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Syneos Health
- Target Recruit Count
- 32
- Registration Number
- NCT06435039
Study to Evaluate the AIO-001 in Healthy Participants
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Syneos Health
- Target Recruit Count
- 16
- Registration Number
- NCT06170827
- Locations
- 🇦🇺
Q-Pharm Pty Ltd, Herston, Queensland, Australia
Dose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol
- Conditions
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Syneos Health
- Target Recruit Count
- 41
- Registration Number
- NCT05896969
- Locations
- 🇦🇺
Cmax Clinical Research, Adelaide, South Australia, Australia
🇦🇺Nucleus Network Pty Ltd, Melbourne, Victoria, Australia
Evaluation of Recombinant Norovirus Hexavalent Vaccine in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Syneos Health
- Target Recruit Count
- 60
- Registration Number
- NCT05805618
Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APB-R3
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Syneos Health
- Target Recruit Count
- 31
- Registration Number
- NCT05715736
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
To Assess the Safety, Tolerability and Pharmacokinetics of ACH-000029 in Healthy Subjects
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Syneos Health
- Target Recruit Count
- 8
- Registration Number
- NCT05363839
- Locations
- 🇦🇺
Nucleus Network Pty Ltd, Melbourne, Victoria, Australia
Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Syneos Health
- Target Recruit Count
- 53
- Registration Number
- NCT05088369
- Locations
- 🇦🇺
Nucleus Network Pty Ltd, Herston, Queensland, Australia
Biosimilar Study Comparing PK, PD, Safety and Immunogencity of BP11 With US Licensed Xolair and EU Approved Xolair
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Syneos Health
- Target Recruit Count
- 165
- Registration Number
- NCT05053334
- Locations
- 🇦🇺
Q-Pharm Pty Ltd, Herston, Queens Land, Australia
🇳🇿Auckland Clinical Studies Ltd (NZCR OpCo Limited), Grafton, Auckland, New Zealand
🇳🇿Christchurch Clinical Studies Trust Ltd (NZCR OpCo Limited), Christchurch, New Zealand
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Syneos Health
- Target Recruit Count
- 40
- Registration Number
- NCT04993443
- Locations
- 🇦🇺
Nucleus Network Melbourne, Melbourne, Victoria, Australia
🇦🇺Q-Pharm Pty Ltd (Nucleus Network Brisbane), Brisbane, Queensland, Australia
First-in-Human Study of VB0004 in Healthy Subjects and to Patients With Mild to Moderate Hypertension With Low Cardiovascular Risk
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Syneos Health
- Target Recruit Count
- 88
- Registration Number
- NCT04925050
- Locations
- 🇦🇺
Nucleus Network Pty Ltd, Victor Harbor, Melbourne, Australia
🇦🇺Scientia Clinical Research, Randwick, New South Whales, Australia
🇦🇺Nucleus Network Pty Ltd Geelong Site, Geelong, Victoria, Australia